Tradestie Institutional Equity Comparison Engine

CRSP vs ACAD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ACAD Overall Edge

ACAD Captures Institutional Edge (4โ€“0 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Acadia Pharmaceuticals Inc. (ACAD) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CRSP trades at 23.4x Forward P/E with -2058.6% operating margin (+1325.1% YoY revenue) versus ACAD at 17.8x Forward P/E and 10.2% operating margin (+22.8% YoY). In options structure, CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against ACAD sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ACAD
CRSP 23.4x vs ACAD 17.8x Fwd P/E
Growth & Margin Winner ACAD
Op Margin -2058.6% vs 10.2% ยท YoY +1325.1% vs +22.8%
Momentum & Technical Winner ACAD
1Y -20.5% vs -19.3% ยท 52W Pos 1% vs 21%
Options & Structure Winner ACAD
BREAKDOWN (52nd %ile IV) vs BREAKDOWN (4th %ile IV)
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
1M Return -17.54%
1Y Return -20.54%
Forward P/E 23.4x
Unified AI Score
48.6 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0
ACAD NASDAQ
Acadia Pharmaceuticals Inc.
Pharmaceutical Preparations
$19.07
+1.71% 1D
Market Cap $3.1B
1M Return -0.26%
1Y Return -19.33%
Forward P/E 17.8x
Unified AI Score
46.7 / 100 HOLD
Tech 41.0 Fund 52.0 Flow 68.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRSP -20.54% ACAD -19.33% Spread: +1.21 pp (ACAD Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CRSP Revenue ACAD Revenue CRSP Op. Margin ACAD Op. Margin Margin Edge
FY2018 $0M $220M -5087.8% -110.6% ACAD
FY2019 $290M $340M 16.1% -72.7% CRSP
FY2020 $0M $440M -49295.5% -64.9% ACAD
FY2021 $910M $480M 40.8% -35.2% CRSP
FY2022 $0M $520M -56190.4% -43.2% ACAD
FY2023 $370M $730M -60.0% -10.1% ACAD
FY2024 $40M $960M -1250.4% 24.1% ACAD
FY2025 $0M $1.07B -18933.6% 9.8% ACAD

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRSP (4) vs ACAD (6)
Institutional Metric CRSP ACAD Criterion Row Winner
Market Capitalization Scale $4.1B $3.1B Larger Scale CRSP
Trailing P/E Ratio Valuation 23.4x 8.6x Lower Multiple ACAD
Forward P/E Ratio Valuation 23.4x 17.8x Lower Multiple ACAD
Revenue Growth (YoY) Growth +1325.1% +22.8% Higher Growth CRSP
Operating Margin (TTM) Profitability -2058.6% 10.2% Higher Margin ACAD
Net Profit Margin Profitability 0.0% 30.1% Higher Margin ACAD
Return on Equity (ROE) Capital Efficiency -25.6% 31.4% Higher ROE ACAD
52-Week Range Position Momentum 1% ($40โ€“$63) 21% ($16โ€“$31) Stronger Trend ACAD
Beta / 30D Volatility Risk Regime 1.85ฮฒ ยท 60% Vol 0.11ฮฒ ยท 93% Vol Lower Realized Risk CRSP
Unified Institutional Score Composite Signal 48.6 / 100 (HOLD) 46.7 / 100 (HOLD) Higher Composite CRSP

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRSP vs ACAD Buy Guide
CRSP BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CRSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ACAD BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live ACAD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRSP nor ACAD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.